This week’s episode dives into one of the most exciting moments we’ve seen yet in obesity medicine. We break down brand-new data on Wave Life Sciences’ single-injection therapy—showing visceral fat loss, total fat reduction, and even increased lean muscle—marking a major shift toward “quality of weight loss,” not just the number on the scale. We also explore the latest on amylin drugs from Novo Nordisk and Eli Lilly, updates on oral GLP-1s like orforglipron and alaniglipron, and why maintenance therapies are becoming the next big frontier. Dave also covers the ongoing counterfeit Ozempic problem and what patients need to look for. It’s a packed episode with everything you need to understand where obesity treatment is headed next.